
Molecular diagnostics startup Swift Biosciences Inc. pulled in a $3 million Series A investment.
The Ann Arbor, Michigan-based company is developing molecular biology reagents, which help scientists and doctors conduct genetic tests to identify whether patients are susceptible to specific diseases.
Reagents are chemicals used in lab settings to bring about a reaction or determine whether a chemical reaction has occurred.
Swift plans to use the funding to bring its product to market more quickly, according to a statement from the company.
Houston-based DFJ Mercury led the funding round, which included participation from several individual investors.
Swift CEO David Olson is the former chief scientific officer for Ann Arbor, Mich.-based medical device startup Accuri Cytometers, which recently raised $6 million.